All News

2018

July

Media Release / Jul 30, 2018

Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention

Read More
Digital tools in neuroscience
Story / Jul 30, 2018

Quest for a new measure of mental health

Novartis researchers are searching for more effective ways to discover drugs for neurological and psychiatric diseases.

Read More

June

Media Release / Jun 28, 2018

Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine

Read More
Media Release / Jun 01, 2018

Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine

Read More

May

Media Release / May 18, 2018

Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention

Read More
Media Release / May 15, 2018

Novartis successfully completes acquisition of AveXis, Inc.

Read More

April

Media Release / Apr 20, 2018

New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients

Read More
Media Release / Apr 19, 2018

Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer

Read More
Media Release / Apr 19, 2018

Novartis delivered a strong first quarter and acted to become a more focused medicines company

Read More
Media Release / Apr 17, 2018

Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More